Drug industry
Article Abstract:
Investors must be cautious in selecting pharmaceutical companies for investment purposes throughout 1996 and can no longer use the guidelines that proved so successful in 1995. Although earnings for some pharmaceutical companies will show double digit increases and acquisitions and mergers should continue, these factors will not necessarily guarantee good stock performance, as demonstrated by results in the 1st qtr 1996 when earnings acceleratwd and stock prices dropped.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Biotechnology industry
Article Abstract:
Share prices for biotechnology companies have increased in 2001 and are well-ranked for performance in the coming 12 months. A shift, also, from drug development to genome research is taking place within the industry. Several of these stocks have appreciation potential in spite of the industry's volatile nature.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Biotechnology industry
Article Abstract:
Issues are presented concerning the performance of securities in the Biotechnology Industry sector. Statistics detailing the performance of individual companies within the sector are included.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2001
User Contributions:
Comment about this article or add new information about this topic: